Research Studies for Multiple Sclerosis
This study is being done to see how effective and tolerable ublituximab is when given to people who had been receiving different anti-CD20 therapy for relapsing multiple sclerosis. Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis. The EFC17504/FREXVIVA trial is a Phase III clinical trial designed to test how the investigational study drug works and whether it is safe. The investigational study drug (frexalimab, which is administered intravenously) will be compared to placebo (which looks like the investigational study drug but has no therapeutic effect). The purpose of this trial is to compare the investigational study drug or placebo to see if the investigational study drug can possibly delay disease progression in patients diagnosed with secondary progressive multiple sclerosis (SPMS). You will have a 2 in 3 chance of receiving frexalimab. The length of study treatment will be between 27 to 51 months, depending on the moment when you start your participation. You may qualify for this study if you: The EFC17919/FREXALT trial is a Phase III clinical trial designed to assess the safety and efficacy of the investigational study drug against an existing treatment medication in RMS, teriflunomide. The investigational study drug (frexalimab, which is administered intravenously) will be compared to teriflunomide (oral tablets). The purpose of this trial is to compare the investigational study drug to teriflunomide to see if the investigational study drug can possibly reduce the relapse frequency, and/or delay disease progression patients diagnosed with RMS. Participants will be randomly selected to receive frexalimab or teriflunomide. The duration of study treatment will be between 20 to 40 months, depending on the moment when you start your participation. You may qualify for this study if you: See if one of our Research Studies may be a good fit for you... Call us at 781-551-5812 or fill out the online appointment form...
For more information about the FREXVIVA study, and to see if you may qualify, please email ResearchNCNE@neurocenterne.com / call 781-551-5812 opt.2.
Have a current diagnosis of relapsing forms of multiple sclerosis
For more information about the FREXALT study, and to see if you may qualify, please email ResearchNCNE@neurocenterne.com / call 781-551-5812 opt.2.
This is an observational study designed to collect information on patients who plan to or have recently started treatment with Briumvi® (ublituximab), an FDA-approved disease modifying therapy (DMT) for MS. The study is being conducted to characterize the safety and effectiveness of Briumvi® in older adult patients with MS.
You may qualify for the study if you:
For more information about this observational study, and to see if you may qualify, please email ResearchNCNE@neurocenterne.com
Request Information
Want to request an Appointment?